Analyst Price Targets — FOLD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 22, 2026 8:11 am | Dennis Ding | Jefferies | $14.50 | $14.35 | StreetInsider | Jefferies Downgrades Amicus Therapeutics (FOLD) to Hold |
| December 19, 2025 2:29 pm | — | Cantor Fitzgerald | $14.50 | $14.25 | TheFly | Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald |
| September 18, 2025 10:18 am | — | Needham | $14.00 | $8.31 | TheFly | Needham upgrades Amicus to Buy on reduced regulatory risk |
| October 17, 2024 11:06 am | Tazeen Ahmad | Bank of America Securities | $15.00 | $12.03 | StreetInsider | Amicus Therapeutics (FOLD) PT Raised to $15 at BofA Securities |
| May 14, 2024 6:19 am | Debjit Chattopadhyay | Guggenheim | $13.00 | $9.04 | TheFly | Amicus upgraded to Buy from Neutral at Guggenheim |
| May 9, 2024 12:03 pm | Jeffrey Hung | Morgan Stanley | $19.00 | $9.48 | StreetInsider | Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley |
| December 19, 2023 3:12 am | Jeffrey Hung | Morgan Stanley | $20.00 | $12.66 | StreetInsider | Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight |
| May 10, 2021 12:00 am | Salveen Richter | Goldman Sachs | $14.00 | $9.39 | StreetInsider | Amicus Therapeutics (FOLD) PT Lowered to $14 at Goldman Sachs |
Latest News for FOLD
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118,696 shares of the biopharmaceutical company's stock after selling 42,506 shares during the period. Amicus
Guru Stock PicksGeorge Soros has made the following transactions:Reduce in SPSB by 5.19%Sold out in MMYTAdd in AAMI by 61.3%New position in COINStock News Blue
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for…
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FOLD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.